Glucagon-Like Peptide-1 Receptor Agonists and Risk of Gastrointestinal Cancers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
2024; Elsevier BV; Volume: 208; Linguagem: Inglês
10.1016/j.phrs.2024.107401
ISSN1096-1186
AutoresGisella Figlioli, Daniele Piovani, Spyros Peppas, Nicola Pugliese, Cesare Hassan, Alessandro Repici, Ana Lleo, Alessio Aghemo, Stefanos Bonovas,
Tópico(s)Neuroendocrine Tumor Research Advances
ResumoGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly used for glucose lowering and weight-loss. However, their association with gastrointestinal cancer remains uncertain. This meta-analysis assesses the risk of gastrointestinal cancer in patients treated with GLP-1 RAs.
Referência(s)